NasdaqCM - Delayed Quote USD

INVO Bioscience, Inc. (INVO)

0.9143

-0.0147

(-1.58%)

At close: 4:00 PM EDT

INVO Reports Record First Quarter 2024 Financial Results

353% Revenue Growth with improvement in Adjusted EBITDASARASOTA, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the establishment and acquisition of fertility clinics, and with the intravaginal culture ("IVC") procedure enabled by its INVOcell® medical device, today announced financial results for the first quarter of 2024 and provide

GlobeNewswire 6 days ago

INVO
-1.58%
INVO Reports Fourth Quarter and Full Year 2023 Financial Results

SARASOTA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the establishment and acquisition of fertility clinics, and with the intravaginal culture ("IVC") procedure enabled by its INVOcell® medical device, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a business update.

GlobeNewswire last month

INVO
-1.58%
NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)

NAYA to accelerate Phase II clinical development and Early Patient Access after initial safety demonstrated in 28-patient clinical trialProgram developed by Florida Biotechnologies, Inc. & the University of Miami’s Bascom Palmer Eye InstituteNAYA continuing to implement acquisition roll-up of clinical and commercial assets in oncology, regenerative medicine, and fertilityNAYA expects to close its previously announced merger with INVO Bioscience (NASDAQ: INVO) in the first quarter of 2024 followi

GlobeNewswire 3 months ago

INVO
-1.58%
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors

INVO (NASDAQ: INVO) and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024Experienced, entrepreneurial leadership team to help structure merged public company and accelerate growth SARASOTA, Fla. and AVENTURA, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, a healthcare services company focused on expanding access to advanced fertility treatment worldwide, which has recently signed a definitive merger agreement with NAYA Biosciences (“NAYA”)

GlobeNewswire 4 months ago

INVO
-1.58%
NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal

NAYA Biosciences Inc. ("NAYA"), a company which has recently signed a definitive merger agreement with INVO Bioscience to establish an expanded, publicly-traded life science company dedicated to increasing patient access to breakthrough treatments in fertility, oncology, and regenerative medicine, today announced that new data for its CD38-targeted Flex-NK™ Bispecific Antibody (NY-338, formerly CYT-338) for the treatment of Multiple Myeloma (MM) was published as an abstract in the 2023 American

PR Newswire 5 months ago

INVO
-1.58%
NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies

NAYA Biosciences Inc. ("NAYA"), a company which has recently signed a definitive merger agreement with INVO Bioscience to establish an expanded, publicly-traded life science company dedicated to increasing patient access to breakthrough treatments in fertility, oncology, and regenerative medicine, and ONK Therapeutics ("ONK"), an innovative cell therapy company dedicated to developing the next generation of optimally engineered off-the-shelf natural killer (NK) cell therapies, today announced th

PR Newswire 5 months ago

INVO
-1.58%
INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services company focused on expanding access to advanced fertility treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced the Company received notice from The Nasdaq Capital Market, LLC ("Nasdaq"), dated November 22, 2023, informing INVO that it has regained compliance with the minimum stockholders' equity requirement as set forth under NASDAQ Lis

PR Newswire 5 months ago

INVO
-1.58%
INVO Reports Record Third Quarter 2023 Financial Results

INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the third quarter ended September 30, 2023 and provided a business update.

PR Newswire 6 months ago

INVO
-1.58%
NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending Merger

INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO"), a healthcare services company focused on expanding access to advanced fertility treatment worldwide, and NAYA Biosciences Inc. ("NAYA"), a company dedicated to increasing patient access to breakthrough treatments in oncology and regenerative medicine, today jointly announced that following the closing of their pending merger, Dr. Peter Kash, Ed.D., MBA will join the combined company's Board of Directors as Vice Chairman.

PR Newswire 6 months ago

INVO
-1.58%
INVO Bioscience Announces Commencement of Waiver Solicitation From Holders of the Company's Common Stock Purchase Warrants

INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services company focused on expanding access to advanced fertility treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, announced that it is soliciting waivers (the "Waiver Solicitation") from holders of the Company's common stock purchase warrants dated August 8, 2023 (the "Warrants") of the holder's right to exercise a cash payment option upon consummation of

PR Newswire 6 months ago

INVO
-1.58%
Free Registration Is Now Open For Tribe Public's CEO and Q&A Presentation Webinar Event "Accelerating Biotech Value Creation" Featuring NAYA Biosciences CEO Dr. Daniel Teper On Tuesday, October 31, 2023

INVO Bioscience ("INVO") and NAYA Biosciences ("NAYA"), two companies which recently signed a definitive merger agreement, today announced that NAYA CEO Dr. Daniel Teper will present at Tribe Public's Webinar Presentation and Q&A Event, titled "Accelerating Biotech Value Creation" . The event is scheduled to begin at 8:30AM PST/11:30AM EST on Tuesday, October 31, 2023. To register to join the complimentary event, please visit the Tribe Public LLC at NAYAOCT3123.TribePublic.com.

PR Newswire 6 months ago

INVO
-1.58%
INVO Bioscience and NAYA Biosciences Announce Definitive Merger Agreement To Establish Expanded Publicly Traded Life Science Company

INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO"), a healthcare services company focused on expanding access to advanced fertility treatment worldwide, and NAYA Biosciences Inc. ("NAYA"), a company dedicated to increasing patient access to breakthrough treatments in oncology and regenerative medicine, today jointly announced that they have entered into a definitive merger agreement (the "Merger") for INVO to acquire NAYA Biosciences in an all-stock transaction. Under the terms of the agreement, NAYA

PR Newswire 6 months ago

INVO
-1.58%
INVO to Participate in the Lytham Partners Fall 2023 Investor Conference

INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, announced today that Steve Shum, CEO, will be participating in a Panel Presentation at the Lytham Partners Fall 2023 Investor Conference on Tuesday, October 17, 2023. Management will also be conducting one-on-one meetings with investors.

PR Newswire 7 months ago

INVO
-1.58%
INVO BIOSCIENCE ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF SHAREHOLDERS

INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company") today announced that its special meeting of shareholders on September 29, 2023 (the "Special Meeting") was convened and then adjourned, without conducting any business, in order to provide shareholders additional time within which to vote on the proposals as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on September 1, 2023 (the "Proxy Statement").

PR Newswire 7 months ago

INVO
-1.58%
INVO Reminds Shareholders to Cast Their Vote for Upcoming Special Meeting of Shareholders to be held on Friday, September 29, 2023 at 12:00 p.m. ET

INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, reminds its shareholders to vote ahead of the upcoming special meeting of shareholders (the "Special Meeting") to be held on September 29, 2023 at 12:00 pm (Eastern time). The Board of Directors of INVO (the "Board") unanimously recommends tha

PR Newswire 7 months ago

INVO
-1.58%
INVO Reports Second Quarter 2023 Financial Results

INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the second quarter ended June 30, 2023 and provided a business update.

PR Newswire 9 months ago

INVO
-1.58%
INVO Closes Acquisition of Wisconsin Fertility Institute

INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced it has closed the previously announced acquisition of Wisconsin Fertility Institute. The acquisition provides operational scale, positive cash flow and complements the Company's new-build INVO Center strategy.

PR Newswire 9 months ago

INVO
-1.58%
INVO to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

INVO Bioscience, Inc. (NASDAQ: INVO), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, will report financial results for its second quarter 2023, for the period ended June 30, 2023, after the market close on Monday, August 14, 2023. The Company has scheduled a conference call that same day, Monday, August 14, 2023, at 4:30 pm ET, to review the results.

PR Newswire 9 months ago

INVO
-1.58%
INVO Bioscience Announces Closing of $4.5 Million Public Offering

INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced the closing of its public offering of 1,580,000 units, with each unit consisting of one share of common stock and two warrants, each to purchase one share of common stock. Each unit was sold at a public offering price of $2.85.

PR Newswire 9 months ago

INVO
-1.58%
INVO Bioscience Announces Pricing of $4.5 Million Public Offering

INVO Bioscience, Inc. (Nasdaq:INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced the pricing of its public offering of 1,580,000 units, with each unit consisting of one share of common stock and two warrants, each to purchase one share of common stock. Each unit is being sold at a public offering price of $2

PR Newswire 9 months ago

INVO
-1.58%

Performance Overview

Return	INVO	S&P 500
YTD	-32.27%	+11.56%
1-Year	-88.19%	+26.94%
3-Year	-98.91%	+27.95%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

INVO Bioscience, Inc. (INVO)

INVO Reports Record First Quarter 2024 Financial Results

INVO Reports Fourth Quarter and Full Year 2023 Financial Results

NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)

INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors

NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal

NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies

INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

INVO Reports Record Third Quarter 2023 Financial Results

NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending Merger

INVO Bioscience Announces Commencement of Waiver Solicitation From Holders of the Company's Common Stock Purchase Warrants

Free Registration Is Now Open For Tribe Public's CEO and Q&A Presentation Webinar Event "Accelerating Biotech Value Creation" Featuring NAYA Biosciences CEO Dr. Daniel Teper On Tuesday, October 31, 2023

INVO Bioscience and NAYA Biosciences Announce Definitive Merger Agreement To Establish Expanded Publicly Traded Life Science Company

INVO to Participate in the Lytham Partners Fall 2023 Investor Conference

INVO BIOSCIENCE ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF SHAREHOLDERS

INVO Reminds Shareholders to Cast Their Vote for Upcoming Special Meeting of Shareholders to be held on Friday, September 29, 2023 at 12:00 p.m. ET

INVO Reports Second Quarter 2023 Financial Results

INVO Closes Acquisition of Wisconsin Fertility Institute

INVO to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

INVO Bioscience Announces Closing of $4.5 Million Public Offering

INVO Bioscience Announces Pricing of $4.5 Million Public Offering

Performance Overview